Gilead Sciences Inc articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2014/04/24 20:34
2014/04/24 20:34
1m
Here are the ten most active Big Board issues at this time SPDR S&P 500 ETF Trust up .410 187.860 Bank of America Corp up .025 16.395 iShares Russell 2000 ETF down .300 113.600 Verizon...
2014/04/24 20:34
2014/04/24 20:34
Latest videos
2014/04/24 16:49
2014/04/24 16:49
3h
Add Aetna Inc. to the list of insurers that don’t seem to have any problems with Obamacare. Reporting its first-quarter earnings Thursday, Aetna /quotes/zigman/272706/delayed/quotes/nls/aetAET posted...
2014/04/23 18:34
2014/04/23 18:34
1d
A Wall Street sign is pictured outside the New York Stock Exchange in New York. New York - US stocks edged lower on Wednesday as weakness in AT&T and biotech names inspired investors to take profits...
2014/04/23 16:25
2014/04/23 16:25
1d
Wall St lower after sustained rally Wednesday, April 23 16:29:00 U.S. stocks edged lower today as strong results from Boeing failed to inspire investors to keep pushing equities higher following six...
2014/04/23 12:27
2014/04/23 12:27
1d
Futures flat after six straight days of gains NEW YORK (Reuters) - U.S. stock index futures were flat on Wednesday as investors found few reasons to keep buying following six straight days of gains...
2014/04/23 12:18
2014/04/23 12:18
1d
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) ha anunciado hoy sus resultados de las operaciones correspondientes al cuarto trimestre cerrado el 31 de marzo, 2014. Los...
2014/04/23 08:41
2014/04/23 08:41
1d
As a graduate student at Harvard Medical School in the 1990s, Robert Means had his name on 18 publications. Currently, Means is a professor of pathology at the Yale School of Medicine, as well as...
2014/04/22 21:49
2014/04/22 21:49
1d
Gilead Sciences Inc. soundly beat earnings forecasts on Tuesday thanks to its pricey hepatitis C drug, but the biotech giant wasn’t getting the after-hours love one might expect from such strong...
2014/04/19 05:44
2014/04/19 05:44
5d
Investors hope Wall St to get boost from first qrtr earnings Several behemoths due to report results NEW YORK, April 18, (RTRS): Earnings season shifts into high gear next week, and with nearly...
2014/04/18 17:27
2014/04/18 17:27
6d
Exclusive: Biogen prices hemophilia drug on par with older therapies Related Topics The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which...
2014/04/18 09:07
2014/04/18 09:07
6d
UnitedHealth Group's first-quarter net income slid 8 percent as funding cuts to a key product and costs imposed by the health care overhaul dented the health insurer's performance.The Minnetonka,...
2014/04/17 22:49
2014/04/17 22:49
6d
Not readily apparent in Thursday’s earnings report from UnitedHealth Group Inc. was the notion that the company faces cost concerns over expensive new treatments for hepatitis C, an issue that is...
2014/04/17 15:46
2014/04/17 15:46
7d
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: Amgen Inc. rose $.03 or percent, to $115.57. Biogen Idec fell $1.38 or .5 percent, to $290.10. Celgene Corp. fell...
2014/04/15 21:17
2014/04/15 21:17
8d
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2014 financial results will be released on Tuesday, April 22, at 4:05 p.m. Eastern...
2014/04/15 19:09
2014/04/15 19:09
9d
Johnson & Johnson, the world's biggest maker of health-care products, beat expectations and raised its 2014 forecast by focusing on new drugs and reducing its reliance on medical devices. The drug...
2014/04/12 22:10
2014/04/12 22:10
11d
Twenty-five years after scientists first identified the hepatitis C virus, doctors are declaring victory over an infection that afflicts more than 3 million Americans and kills more of them than...
2014/04/12 12:18
2014/04/12 12:18
12d
LONDEN--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) heeft vandaag gegevens bekendgemaakt van twee fase 2-studies en een compassionate-access-studie (studie met bijzondere toegang uit...
2014/04/12 09:17
2014/04/12 09:17
12d
LONDRES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a aujourd’hui annoncé les données de deux études Phase 2 et d’une étude d’accès élargi à des fins humanitaires dans laquelle un régime...
2014/04/11 22:18
2014/04/11 22:18
12d
LONDON--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD), hat heute Daten aus zwei Phase-2-Studien und einer Compassionate-Access-Studie (in etwa: anteilnehmender Zugang) bekannt gegeben, bei...
2014/04/11 22:18
2014/04/11 22:18
12d
LONDRA--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) ha comunicato oggi i dati derivati da due studi di Fase 2 e da uno studio di accesso compassionevole in cui un regime contenente Sovaldi®...
2014/04/24 20:34
2014/04/24 20:34
Latest from Twitter